Frequently asked questions
The global narcolepsy drugs market was valued at USD 2748.5 Million in 2022.
The narcolepsy drugs market is expected to grow at a CAGR of 9.9% between 2023 and 2030, reaching USD 5848.9 Million in 2030.
Stimulants are the leading segment by drug class, holding over 30% share in value in 2022.
The excessive daytime sleepiness (EDS) segment governs the global demand for narcolepsy drugs, holding a massive market share of over 35% in 2022.
The clinics segment will post the highest CAGR in the projection period.
North America is driving the rapid growth of the narcolepsy drugs industry, accounting for more than one-third of its market share in 2022.
The top players include Arena Pharmaceutical Inc, Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Inc, Shinogi Inc, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Harmony Biosciences, Novartis AG, Rhodes Pharmaceuticals L.P., and Others.
The major market drivers of the narcolepsy drugs industry include increasing prevalence and diagnosis rates of narcolepsy, ongoing research and development efforts, rising awareness of sleep disorders, and regulatory incentives for orphan drug status.
The major market restraints of the narcolepsy drugs industry include complex and lengthy regulatory approval processes, safety concerns regarding the potential for drug misuse, high development costs, and the challenges of balancing treatment needs with potential risks.
The major market opportunities in the narcolepsy drugs industry include expanding into emerging markets with growing healthcare access, tapping into previously underserved patient populations, and leveraging advancements in drug development and personalized medicine to provide more effective and tailored treatments for narcolepsy.